Husch Blackwell LLP
Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.
H. Lee Moffitt Cancer Center and Research Institute, Inc. Provectus Pharmatech, Inc.
A A A A C C A A A A A A C A C A A
A61K A61P A61K A61K C12P C07K A61P A61K A61K A61K A61K A61K C12P A61P C07K A61K A61P
inventional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional additional additional inventional
Hao Shari Amod Eric Jamie
Liu Pilon-Thomas Sarnaik Wachter Singer